ArticleWorld journal of psychiatry2025
Novel biomarkers of the Framingham risk score in patients with depression: A cross-sectional study.
Article in World journal of psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of coronary heart disease (CHD) is higher in patients with depression than in the general population. Recently, multiple novel biomarkers have been proposed to predict CHD risk, and these factors have been reported to be altered in patients with depression.
aimTo explore whether these new biomarkers are associated with an increased risk of CHD in patients with depression.
methodsWe recruited 279 healthy controls and 164 sex- and age-matched patients with depression and collected their clinical characteristics and laboratory values of novel cardiovascular biomarkers. The Framingham CHD risk score was used to assess the CHD risk of all individuals, and the cardiovascular markers related to the CHD risk in patients with depression were analyzed.
resultsPatients with depression had an increased CHD risk of 5.3% (95% confidence interval: 4.470-6.103) and altered novel cardiovascular biomarkers compared to healthy controls, which included lower levels of thyroid stimulating hormone, albumin, total bilirubin, total cholesterol, high-density lipoprotein cholesterol, and higher levels of triglyceride (TG) and uric acid. Further regression analysis showed that illness duration, family history of depression, serum TG, and urea acid levels were significantly correlated with the Framingham risk score in patients with depression.
conclusionPatients with depression had a higher CHD risk and that their illness duration, family history of depression, serum TG, and uric acid levels could play important roles in predicting CHD risk. Moreover, elevated CHD risk in patients with depression was not only related to physiological changes caused by depression but also to their genetic susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.